JPMorgan analyst Cory Kasimov views the label for Puma Biotechnology's breast cancer drug Nerlynx as a best case outcome. The label does not limit the patient population to HR+, as many investors expected, and does not include a boxed warning as diarrhea is in the warnings and precautions section, Kasimov tells investors in a research note. The analyst sees room for the shares to move "materially higher" given the "scarcity value of an approved and unencumbered" oncology asset as well as the 20% short interest in the name. He reiterates an Overweight rating on Puma Biotechnology.